.gif) |
|
|
|
|
|
|
|
|
|
Optimizing Doctor Visits -
PDF
Print on both sides of
page to create a free
tri-fold brochure
|
|
|
|
|
|
Update to Factors Influencing Treatment Decisions -
Regarding the Clinical Context
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preclinical - Prognosis E-news:
Targeting
tumor resistance mechanism
“All tumors
develop resistance to anti-cancer drugs at least
partly because their normal tumor suppressor
proteins are kicked out of the nucleus.”
|
|
|
|
|
|
|
|
|
QOL - Medscape:
First Study Ever of Long-Term Problems After HCT
(free login required for access.)
“Hematopoietic cell
transplant (HCT) offers the only potential for a cure
for many hematological cancers; however, although the
cancer may be cured by the transplant, the recipients
remain at risk for psychological and chronic health
conditions.” |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Take as Directed:
Pseudoscience Sunday
David Kroll Phd,
friend and advisor to PAL pointed us to several
interesting stories today.
|
|
|
|
|
|
|
|
|
CLL - Patient Power:
Reflections and Major Developments in CLL from ASH 2011
Dr. Keatings explains why
he is more excited than ever before about prospects for
progress against CLL |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FL , origins of -
AACR: Study of Two Sisters Sheds Light on Lymphoma
Evolution Also
see
“this case gave
scientists the unique opportunity to understand the
genetic abnormalities that led to follicular lymphoma in
both cases.” |
|
|
GVHD, SCT - News Medical:
Breakthroughs in hematopoietic cell transplantation to
be presented at 53rd ASH meeting | See
also
“study reveals that
peripheral blood stem cell (PBSC) transplants from
unrelated donors are associated with higher rates of
chronic graft-versus-host-disease (GVHD) and have no
survival advantage when compared to transplants using
stem cells taken from the bone marrow.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASH
reports by ASH
Such as:
SCT -
Studies Investigate New Methodologies to Improve
Recovery and Survival Strategies for Patients Undergoing
Hematopoietic Cell Transplantation
“Although PBSCs from
related donors have demonstrated clinical benefits, our
trial demonstrates that when these stem cells originate
from unrelated donors they are not superior to bone
marrow stem cells in terms of patient survival, and they
increase the risk for chronic GVHD,” said lead author
Claudio Anasetti, MD, Chair of the Department of Blood &
Marrow Transplant at Moffitt Cancer Center in Tampa,
Fla. “More effective strategies to prevent GVHD are
needed to improve outcomes for all patients receiving
unrelated donor transplants.”
|
|
|
|
|
|
|
|
|
|
|
|
MSKCC: Excellent
videos on Stem Cell Transplants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancernet:
Cancer Rehabilitation
Cancer rehabilitation
helps a person with cancer obtain the best physical,
social, psychological, and work-related functioning
during and after cancer treatment.
|
|
|
|
|
|
|
|
|
|
|
|
Neurologica Blog:
You too can be a Snake Oil Salesman
“Next come up with a
marketing angle, some target demographic or condition
you want to claim to help. Name your product something
that suggests it will help with the identified
condition. Then simply claim that your product “may”
help, or that it will boost the immune system or support
the body’s ability to heal from or deal with the
condition.” |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASCO:
Cancer Survivorship - Free Booklet
“Your life may be forever
changed by cancer. Some people talk about appreciating
life more and gaining a greater acceptance of self after
their cancer treatment ends. Others become anxious about
their health and unsure of how to cope with life’s
demands. In some ways, moving from the period of “active
treatment” into survivorship is one of the most complex
aspects of the cancer experience because it is different
for every person." |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology Times:
A certain uncertainty
Harpham, Wendy S. MD - Marveling at my remission, Jane
asks, Wendy, don't you wish you knew if you were cured?
NO! I respond immediately. No? My friend is shocked.
Actually my answer makes perfect sense, since there are
only two ways to know if my cancer is gone for good. If
the lymphoma recurs, I'll know I wasn't cured. If my
cancer is in remission when I die of something else,
I'll know I was. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cure: At Diagnosis: Medical Decisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Len's Cancer Blog:
Steve Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PAL updates:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancer Research UK:
In the news: re-tooling
the body’s police force to beat leukemia
http://bit.ly/qCp7Ge
|
|
|
Cure today:
Why is randomization in clinical
trials important?
http://bit.ly/rlrIcW
|
|
|
Washington Post
‘Comparative effectiveness
research’ tackles medicine’s unanswered
questions
http://wapo.st/nw8hCi
|
|
|
Clinical Oncology News
40 Years of DLBCL
Give CHOP, Add Rituxan-Is that all there is?
http://bit.ly/qofYq7
|
|
|
Clinical Oncology News:
Is Patient Optimism
unrealistic In Early-Phase Trials?
http://bit.ly/nSd5h0
|
|
|
Cancer Network: ASCO 2011:
Steve Joffe
Discusses Controversies in Phase I Clinical
Trials
http://bit.ly/qjQoSH
|
|
|
Annals of Oncology:
Response criteria for
NHL: Importance of 'normal' lymph node size and
correlations with response rates
http://bit.ly/opz6U9
|
|
|
|
|
|
Medscape:
Do Biologics (used for
rheumatologic disease) Cause Cancer
http://bit.ly/qWdAOA
|
|
|
BBC Cancer
Discovery offers hope of tackling
spread of disease
http://bbc.in/rp83Go
|
|
|
Cancer Network:
Novel PARP Inhibitor for Solid Tumors &
Lymphomas
http://bit.ly/n4HY9G
|
|
|
Medical News Today:
Stem Cells Central To
Pathogenesis Of Mature Lymphoid Tumors
http://bit.ly/n4UOYw
|
|
|
University of Copenhagan:
Researchers on the
trail of a treatment for cancer of the immune
system (EBV related blood cancers)
http://bit.ly/pVdrVr
|
|
|
Cancer Research:
In Vivo Programming of
Tumor Antigen-Specific T Lymphocytes from Pluripotent Stem Cells to Promote Cancer
Immunosurveillance
http://bit.ly/nijbfE
|
|
|
Data mining' to generate hypotheses for
testing new indications for existing drugs.
http://bit.ly/peyN5M
|
|
|
Cornell-lymphoma Blog:
Cyclophosphamide may
be associated with an increased risk of
secondary myeloid neoplasia when given with
Fludarabine in CLL
http://bit.ly/mTba5D
|
|
|
Advances in Hematology:
Review Article
Recent Advances in the Pathobiology of Hodgkin's
Lymphoma: Potential Impact on Diagnostic,
Predictive, and Therapeutic Strategies
http://bit.ly/rkgSPH
|
|
|
NY Times: Cancer’s Secrets Come Into Sharper
Focus
http://nyti.ms/nJIfoS
|
|
|
Disappearance of Genetic Material Allows Tumor Cells to
Grow
http://bit.ly/nL0OJq
|
|
|
National Comprehensive Cancer Network:
Cancer
treatment is viewed as a true partnership video
http://bit.ly/mSLcgZ
|
|
|
Health Smart:
Facing Cancer Together General cancer
video
http://bit.ly/pbhLpz
|
|
|
Fox Chase:
IMRT improves outcomes in patients with extranodal
lymphoma of the head and neck
http://bit.ly/pKv5kd
|
|
|
British J of Haematology:
VcR-CVAD induction chemo followed by maintenance Rituxan
in MCL
http://bit.ly/oJwSeH
|
|
|
Medical News Today:
New Drug In Early Clinical Testing Offers New Hope For
Treatment Of Chronic Leukemia
http://bit.ly/r0qVHm
|
|
|
Univ of PA press release:
Triple therapy regime puts patients with leukemic form
of cutaneous lymphoma in remission (Retrospective study)
http://bit.ly/r5zDO3
|
|
|
|
|
|
Is ecstasy ‘being developed to treat blood cancers’?
Not quite…
http://bit.ly/qVaVKu
|
|
|
|
|
|
NCI: Facing Forward: Life After Cancer Treatment
http://1.usa.gov/n5MjjS
|
|
|
WSJ: For Cancer Patients, Help Navigating the Maze
http://on.wsj.com/nrVHU0
|
|
|
KevinMD: Taking the time to answer patient questions
http://bit.ly/ofUNOm
|
|
|
Philly.com: Studying the positive side of Trauma and
Grief
http://bit.ly/pNredd
|
|
|
My Cancer Advisor: Should you get a second opinion
http://bit.ly/q6mB4C
|
|
|
My Cancer Advisor: Preparing for hair loss after
Chemo
http://bit.ly/qBzOfY
|
|
|
My Cancer Advisor: How Do I Get My Medical
Records?
http://bit.ly/rqgr4M
|
|
|
KevinMD.COM: Why developing trust with your doctor is
important
http://bit.ly/nUUAxZ
|
|
|
Medical News Today: Docs Urge Cancer Patients To
Discuss Supplements Before Treatment
http://bit.ly/oObsiM
|
|
|
Retractions
of Scientific Research Papers Going Up
http://bit.ly/o4xuhz
|
|
|
Use of
Chemo Assays Outside Clinical Trials Still a No No
http://bit.ly/p5GbOU
|
|
|
Annual Review 2010/11 – Revolutionizing the way we
diagnose and treat cancer
http://bit.ly/nOdnNI
|
|
|
|
|
|
Video from U Penn on Redirecting T cells trial reported
in NEJM
http://bit.ly/nV1y74
|
|
|
|
|
|
Help
dealing with stress as a cancer caregiver video
http://bit.ly/qM3i7G
|
|
|
Video from U Penn scientist on
http://bit.ly/nV1y74
(Good overview from the scientists, but not much covered
on on risks and preliminary nature of this impressive
new development) |
|
|
Why Some Patients [May] Not Respond To Standard
Lymphoma (Rituxan) Therapy
http://bit.ly/oukJBH
|
|
|
Chemotherapy Primer:
Why? What? and How?
http://bit.ly/mTRKqI
|
|
|
Clinical
guidelines for treatment of follicular lymphoma
http://bit.ly/bFv7hZ
|
|
|
|
|
|
Exercise should be 'standard part of cancer care'
http://bbc.in/nNIgTL
|
|
|
Sorry you're sick, but wow, you're so skinny!
Covetous compliments on illness-related weight loss can
rankle
http://on.today.com/rb1ErH
|
|
|
Before Treatment: Seeking a Second Opinion
http://bit.ly/nn9XT3
|
|
|
|
|
|
|
|
|
Surveillance CT scans are a source of anxiety and
fear of recurrence in long-
term lymphoma survivors
http://bit.ly/d8ODSC
|
|
|
|
|
|
Difference
between hematological malignancy and Solid tumor
research articles
published in four major medical journals
http://bit.ly/oDkj5K
|
|
|
Risk for second malignancies in NHL survivors: a
meta-analysis
http://bit.ly/o6L5Mp
|
|
|
|
|
|
Answers to
questions about sunscreen from MSKCC dermatologist Steven Wang
http://on.fb.me/ov3WbK
|
|
|
|
|
|
Advances in
cancer treatment are hyped by headlines
http://bit.ly/oufHVD
|
|
|
|
|
|
Hospice
medical care for dying patients
http://nyr.kr/di8Mqi
Very difficult to read,
but excellent article on end of life care and
hospice--warning- not for the faint hearted-- but does
raise issues to think about
|
|
|
|
|
|
|
|
|
With
cancer, sometimes there is no right answer
http://bit.ly/oWGYGy
|
|
|
Men, Cancer
& Work: Coming to Terms with the "New Normal"
http://bit.ly/nNu6A2
|
|
|
Patients
want and need to take a greater role in their medical
care
http://bit.ly/mPMe5C
|
|
|
End of life
issues: The Truth About Hospice Care
http://bit.ly/psZOSy
|
|
|
Who's a
Survivor? An oncologist who's had breast cancer
considers the problematic phrase "cancer survivor."
http://bit.ly/ctL1Du
|
|
|
Preclinical: Scientists Strike Genetic Gold in Lymphoma
Study
http://bit.ly/qnts5t
|
|
|
|
|
|
|
|
|
ASCO: Making
e-visits work for cancer patients
http://bit.ly/nR24tK
|
|
|
Planning 'Worry
Time' May Help Ease Anxiety
http://bit.ly/oBI6Bn
|
|
|
Doctors
Differ in How Best to Care for America's 12 Million
Cancer Survivors
http://bit.ly/mUFl9G
|
|
|
On Chemo
brain: Fog May Be From Cancer, Not the Chemo
http://nyti.ms/9vrOJh
|
|
|
Some
supplements claim that they "boost the immune system."
Is this a reasonable claim?
http://bit.ly/q8VjGw
|
|
|
Stay safe
in the ER with life-saving strategies
As many as 98,000 Americans die every year as a result
of medical mistakes
http://on.msnbc.com/ndPaJm
|
|
|
Seeking
Serenity: Serious illness won’t get off my back
http://bit.ly/qJIlI8
|
|
|
Oral
fludarabine and rituxan as initial therapy for
CLL/SLL: population-based experience matches clinical
trials.
http://1.usa.gov/pyCmCX
|
|
|
Lenalidomide associated with durable remissions in
elderly patients with symptomatic CLL
http://bit.ly/pFwbUE
|
|
|
2 genetic
variations predict second cancers after radiation for
children with Hodgkin lymphoma
http://bit.ly/qSoxrU
|
|
|
Rituximab
and/or Lenalidomide in Treating Patients With Follicular
NHL That is Not Refractory to
Rituximab
http://1.usa.gov/oh391X
|
|
|
Lenalidomide and Rituxan in Treating Patients With
Previously Untreated Stage II, Stage III, or Stage IV
Follicular NHL
http://1.usa.gov/nsI9Et
|
|
|
Treatment
Options for Peripheral T-cell lymphoma
http://bit.ly/o4BHH4
|
|
|
Evolving
Therapy of Peripheral T-cell Lymphoma 2010 and Beyond
http://bit.ly/mS54RG
|
|
|
Cutaneous
Lymphoma Patient Educational Opportunities
http://bit.ly/n1HTKy
|
|
|
Combo
Regimen Advised as 2nd-Line Therapy for Waldenstrom's
Macroglobulinemia
http://bit.ly/qnRTIA
|
|
|
Maintenance
Rituxan associated with improved clinical outcome in
rituxan naïve Waldenstrom Macroglobulinaemia who
respond to a rituxan-containing regimen
http://bit.ly/qoo1KA
|
|
|
Analysis of
581 patients with primary intestinal NHL from the
Consortium for Improving Survival of Lymphoma
http://bit.ly/pzqV1V
|
|
|
New Cancer
Treatment? Universal Donor Immune Cells
http://bit.ly/ocd7iD
|
|
|
|
|
|
Specialized
Regulatory T Cell Stifles Antibody Production Centers
http://bit.ly/q9yAp
|
|
|
Histone
modifying genes play a role in non-Hodgkin's lymphoma
http://bit.ly/p7SsG
|
|
|
Research on
tumor microenvironment - Monocytes and T cells cooperate
to favor normal and follicular lymphoma B-cell growth:
role of IL-15 and CD40L signaling
http://bit.ly/nT2rDa
|
|
|
Pitfalls in
lymphoma pathology: avoiding errors in diagnosis of
lymphoid tissues
http://bit.ly/peFZlr
|
|
|
Is routine G-CSF support needed for treatment with ABVD of
Hodgkin lymphoma?
http://1.usa.gov/rv01AP
|
|
|
Lenalidomide + Rituxan Shows Promise as
First-Line Therapy in Patients with Indolent
Lymphoma
http://bit.ly/poj0fD
|
|
|
Caring for Patients With Diabetes and Cancer,
Psarakis, RN, APRN
http://bit.ly/oG4UjY
|
|
|
Revised Response Criteria for Malignant Lymphoma
http://bit.ly/ruWNfW
|
|
|
Social Security's Compassionate
Allowances Program Means So Much To People In Time Of
Need
http://bit.ly/oW0YMo
|
|
|
10 Things To Avoid On Your Resume -
Cancer and Careers
http://bit.ly/nLJOW4
|
|
|
ABVD versus BEACOPP for Hodgkin's
Lymphoma When High-Dose Salvage Is Planned
http://bit.ly/pwq2Ej
|
|
|
ABVD versus BEACOPP summary from medscape--
requires registration: Chemo Toxicity May Tip Scales in
Advanced Hodgkin's Lymphoma
http://bit.ly/mUveA8
|
|
|
What is the lump on this girl's neck?
http://bit.ly/p1NaYe
"Of neck lumps in
children, over 90% are simply reactive nodes "
|
|
|
The Prepared Patient, When Pain Doesn't
END
http://bit.ly/p2S3zK
|
|
|
Phase III trial of CHOP-21 versus
CHOP-14 for aggressive non-Hodgkin's lymphoma: final
results of the Japan Clinical Oncology Group Study, JCOG
9809.
http://1.usa.gov/qVHcKJ
|
|
|
An Oncologist's Pulitzer-Winning Cancer
Biography
http://n.pr/pGxWrG
|
|
|
Treatment of Hodgkin lymphoma with ABVD
without g-csf support
http://1.usa.gov/rv01AP
|
|
|
Brentuximab Vedotin Before Autologous
Stem Cell Transplant in Treating Patients With Hodgkin
Lymphoma
http://1.usa.gov/p48iQa
|
|
|
Add Patience to a Leap of Faith to
Discover Cancer Signatures
http://nyti.ms/mZv4bJ
|
|
|
Battling the Hematological
Malignancies: The 200 Years' War Patients
http://bit.ly/p3f8B6
|
|
|
Researchers Discover Possible Drug
Targets For Common Lymphoma
http://bit.ly/pJutZc
|
|
|
|
|
|
Expert perspective: "Aiming at a
curative strategy for follicular lymphoma" Bendandi
http://bit.ly/oaItLl
|
|
|
Revised Response Criteria for Malignant
Lymphoma
http://bit.ly/ruWNfW
|
|
|
Financial Management During a Loved
One’s Medical Crisis – CarePages.com
http://bit.ly/LnWLy
|
|
|
Clinical Challenges in Caring for
Patients With Diabetes and Cancer
http://bit.ly/oG4UjY
|
|
|
Curr Opin Oncol: Maintenance therapy in
follicular lymphoma.
http://1.usa.gov/q0OXGF
|
|
|
ASCO Post Important Briefs:
Lymphoma research - improved
approaches
http://bit.ly/qlhrUu
|
|
|
FDA Advisor Panel Backs Accelerated Approval of Brentuximab for
Hodgkins Lymphoma and ALCL
http://bit.ly/pr3er1
|
|
|
Stem Cell Treatment May Restore Cognitive Function in Patients
[Treated for] Brain Cancer
|
|
|
PET scans: when and how?
http://bit.ly/qQPoCk
James Olen Armitage
|
|
|
|
|
|
|
|
|
Tips for Getting Through Cancer Treatments
http://bit.ly/qmgt8h
|
|
|
|
|
|
Clinical Questions that Can Only Be
Answered by Clinical Trials
PDF
|
|
|
Autologous stem cell transplantation as a
first-line treatment strategy for CLL: a multicenter, randomized,
controlled trial
http://bit.ly/je7iRh
snip: " This is the first
published randomized clinical trial of ASCT as part of the first-line
treatment for patients with stage B or C CLL. We found that ASCT doubled
the EFS (effect free survival) probability in patients who entered CR
after up-front chemotherapy. This is consistent with the results of
previous phase 2 trials of ASCT for first-line treatment consolidation,
in which the median EFS ranged from 5-6.3 years.19-21 In contrast, ASCT
was not more beneficial than FC in our non-CR patients rescued with DHAP."
|
|
|
Lugano Conference: Rituximab + Lenalidomide Prolonged
Remission in Mantle Cell Lymphoma
http://bit.ly/lVhZmJ
The
researchers found that more than half (57.8%) of patients
responded to treatment, and most responses lasted for at
least 18 months. The combination was very well tolerated,
with few bothersome side effects. These results are
striking for this group of patients, especially as many had
not responded to previous therapy.
|
|
|
Mantle Cell Lymphoma - Rituxan maintenance: EHA 2011: Remission
duration of lymphoma doubled
http://bit.ly/jQ7TIY
"Clinical research has
shown that recurrence of Mantle Cell Lymphoma, a variant of malignant
lymphoma, can be reduced by almost 50% in patients who receive
maintenance treatment with the antibody rituximab. These results are
presented by Dr Hanneke Kluin-Nelemans at the 16th Congress of the
European
Hematology Association in London."
Also see Medcape item:
http://www.medscape.com/viewarticle/744453
|
|
|
Management of Follicular Lymphoma in the Up-Front and Relapsed
Settings http://bit.ly/mjsYzy
snip: “This paper reviews
recent practice patterns in the broad context of the published findings
from major phase III randomized trials; it documents potential gaps
between trial results and actual practice, and the implications of these
for continuing education of oncologists."
|
|
|
|
|
|
A doctor's letter to a patient with newly diagnosed cancer
http://bit.ly/mjDC5T
Reader comment: "That was
a beautifully written, yet very difficult to read example of a frank,
but compassionate communication."
|
|
|
ASCO11: Antibody Drug Conjugates
(ADCs) Are Rapidly Changing The
Landscape of Lymphoma Therapy
facebook.com/notes/lymphoma-resources/
|
|
|
Clinical report showing activity of CD19 antibody + cytotoxic
- maytansinoid (SAR3419)
ASCO 2011
|
|
|
Evaluation of the addition of rituximab to CODOX-M/IVAC for
Burkitt's lymphoma: a retrospective analysis
annonc.oxfordjournals.org
|
|
|
Hope, hype and hypocrisy http://bit.ly/muHf3M
"At a higher level,
scientists are in a fierce competition to maintain and increase public
support and funding, and they oblige and numb their critical
sensitivities to do so. The net effect is that hype and hope have become
common…" |
|
|
Splenic marginal zone lymphoma: hydra with many
heads? http://bit.ly/lAWHaV
Luca
Arcaini1, Marco Paulli2
|
|
|
Rituximab for Follicular Lymphoma: Maintaining an Open Mind
Commentary by Dr. Bruce D. Cheson
http://bit.ly/mxny1J
|
|
|
Being around kids when you receive treatment?
Tips from Patients
|
|
|
RECOMMENDED: 5 rules for living well with a chronic illness
http://bit.ly/k6uect
|
|
|
NPR Walt Bogdanich interview:
[Benefits and] Hidden Dangers Of Medical
Radiation
Includes many useful tips
- questions to ask, who to ask, how to
identify credentialed centers ....
|
|
|
Acetaminophen tied to blood cancers
http://reut.rs/jc93zU
This article could be used as a model for how to explain
such findings. |
|
|
Role of Stem Cell transplant in Follicular lymphoma,
Foster, Gabriel, Shea, 2010
ncbi.nlm.nih.gov
|
|
|
When Laypersons Give medical advice? PAL
|
|
|
Prospective Study of Survival Outcomes in Non-Hodgkin’s
Lymphoma Patients With Rheumatoid Arthritis
jco.ascopubs.org full.pdf
|
|
|
NPR Mukherjee interview
Author of 'The Emperor of all Maladies'
http://n.pr/dEtPXf
|
|
|
Novel therapeutic agents for B-cell lymphoma: developing rational
combinations - Blood 2011 Full text:
http://bit.ly/i7c7qs
Fairly technical but a
useful review of the landscape, providing summary discussion of 1) the
class of drug, the 2) mechanism of activity, 3) its use so far in
lymphoma, and 4) toxicities. |
|
|
State by state health insurance options for people with pre-existing
conditions http://1.usa.gov/fGvYoQ
|
|
|
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy
Produces High CR Rates and Long-Term Disease Free Survival in Patients
with Relapsed Aggressive NHL Who Previously Failed Frontline CHOP
Therapy
http://bit.ly/gLKS4P
|
|
|
Treatment-related Questions for Your Doctor
PAL
|
|
|
8 Survival Tips for the Spouse (or significant other) of a
Terminally Ill Person http://bit.ly/fcy1wl
|
|
|
BEACOPP regimen associated with 97% OS in young patients with
high-risk Hodgkin’s lymphoma
http://bit.ly/hl8w38
|
|
|
Standard Therapy for Mantle Cell Lymphoma?
http://bit.ly/htWQpf
|
|
|
Evaluating FLIPI-2, the Follicular Lymphoma Prognostic Index
journals.lww.com
|
|
|
Interim Results From a Phase 1 Study of CAL-101, a Selective Oral
Inhibitor of PI3K in Patients with Relapsed or Refractory Hematologic
Malignancies Slides ASCO 2010
http://bit.ly/hqMLvL
N =106, (99 evaluable) relapsed/refractory, mixed
histologies (CLL, indolent NHL, DLBC, MCL, AML, MM)
|
|
|
Pre-existing Conditions Health Insurance Plans
http://nyti.ms/hxm6ZO
|
|
|
R-CHOP v. R-CVP in the treatment of follicular lymphoma: a
meta-analysis http://bit.ly/hbYG0W
|
|
|
Relapsed CLL: Does
adding lumiliximab (anti-cd23) improve on FCR?
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810983/
"Thirty-one patients gave
consent and were treated at 5 clinical sites.
|
|
|
Positive
Results With Acadra (Acadesine) in CLL
prnewswire.com
|
|
|
Gorski:
Why haven’t we cured cancer yet?
How many times
have you heard these questions, or variants thereof? How
many times have you asked this question yourself?
|
|
|
How I treat CLL up
front
http://bit.ly/favAVV
John G. Gribben, Institute
of Cancer, Queen Mary University of London, Barts and The London School
of Medicine and Dentistry, London, United Kingdom
|
|
|
Study of
interest:
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced
T Cells From the Original Transplant Donor to Patients With Recurrent or
Persistent B-Cell Malignancies After Allogeneic Stem Cell
Transplantation
NCI-10-C-0054
http://bit.ly/gUw3gV
|
|
|
Lymphoma Clinical Trial Lookup Tool
by subtype and treatment status
PDF |
|
|
Report on Vorinostat (SAHA) for Relapsed Indolent NHL and MCL
http://bit.ly/dGBVLp
See for studies
http://bit.ly/aFsxvB
All 35 eligible patients
were evaluable for response. The median number of vorinostat cycles
received was nine. ORR was 29% (five complete responses [CR] and five
partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR,
four PR). There were two of nine responders with MZL (one CR, one PR),
and no formal responders among the nine patients with MCL, although one
patient maintained stable disease for 26 months. Median PFS was 15.6
months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL.
The drug was well-tolerated over long periods of treatment, with the
most common grade 3 adverse events being thrombocytopenia, anemia,
leucopenia, and fatigue. |
|
|
Novel Agents for Follicular Lymphoma Lymphoma:
Translating Basic Science into Therapy Leonard, Martin
http://bit.ly/hY59Bl
Agents That Target:
Cell Surface molecules (such as anti-CD20 Antibodies)
Cell Surface molecules with immunoconjugates (such RIT, or a toxin bound
to an antibody)
Intracellular Processes (such as CAL101, BTK, MTOR, ...)
Proteasome (such as Velcade)
Microenvironment (such as Lenalidomide)
|
|
|
Dose Intensive R-ACVBP vs Standard R-CHOP In Younger Patients with
DLBCL http://bit.ly/heJlx2
It will be interesting to
see if this result is considered practice changing in Europe for younger
patients (given the tradeoffs - higher risk for significantly better
outcomes) ... and how younger patients in the US feel about this option.
|
|
|
Treatment Approaches for Follicular Lymphoma Continue to Evolve --
An Interview with Dr. Andre Goy
http://bit.ly/fbfIfm Free login registration required
Liz: Interview of Dr.
Andre Goy (pronounced Gwah, he's French) with an excellent, well
balanced run down on the current and emerging landscape in treating FL
in a variety of settings.
|
|
|
Slides only: Managing patients with relapsed follicular
lymphoma: Extending survival through judicious use of available agents,
J. Leonard 2011
http://bit.ly/eAHXui
|
|
|
Ki-67 as a prognostic marker in mantle cell lymphoma—consensus
guidelines of the pathology panel of the European MCL Network
ncbi.nlm.nih.gov
|
|
|
Insuring Your Health:
Looking At The Changes 2011 Brings
http://bit.ly/ibyhZL
Michelle Andrews speaks
with KFF's Jackie Judd about changes in lifetime insurance limits,
keeping children insured, the new high-risk pools.
|
|
|
11 Tips to Help Manage Anxiety
http://bit.ly/dHSGD7
For the last two months I
have been under the very clear direction of my doctor to “distract,
don’t think.” |
|
|
Novel Insights into the Biology of CLL
Lanasa, Asheducation Book 2010
http://bit.ly/eJHpEM
|
|
|
Novel Agents for Follicular Lymphoma, Dec 2010
John P. Leonard1 and Peter Martin
http://bit.ly/dOaSUh
|
|
|
|
|
|
Management of Follicular Lymphoma in the Up-Front and Relapsed
Settings
http://bit.ly/dNGsP5
(might require
free registration) |
|
|
Vaccines and Autism link:
It's easy to
confuse correlation with causation -
Tony L. Hines
|
|
|
Vaccine therapy for EBV-driven lymphomas (Hodgkins and NHL) moving
forward - expanding EBV cytotoxic lymphocytes (CTL) and then infusing
CTLs to delay relapse
http://bit.ly/f8ZKyG
This approach is thought
to cause an immune response to cancerous cells which co-express viral
antigens (which is not the same as having a lymphoma and testing
positive for EBV in the blood) |
|
|
Going Home After Your Autologous Stem Cell Transplant
NYU
|
|
|
Story of hope and perspective
Linda
|
|
|
"You will often find
survival curves inhabiting technical papers in the medical literature,
and some understanding of these curves is essential to understanding the
technical literature." |
|
|
Does Progression Free Survival predict
better survival in Follicular Lymphoma?
PDF
|
|
|
Zevalin-based abstracts at ASH 2010
PAL
|
|
|
Locally Extensive and Advanced Stage Hodgkin's Lymphoma:
ABVD Vs. Stanford V +/- Radiation Therapy
ash.confex.com
|
|
|
Relapsed or Refractory Hodgkin Lymphoma -- Brentuximab Vedotin
(SGN-35)
ash.confex.com
|
|
|
Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous
Hematopoietic Stem Cell Transplant Final Analysis: Phase II Study of
Oral Panobinostat
ash.confex.com
|
|
|
Dr. Anas Younes, a renowned lymphoma expert,
discusses two promising medicines for Hodgkin's
disease and anaplastic large cell lymphoma and gives
his views on whether watch and wait is still a
reasonable approach for B-cell lymphoma patients who
have no symptoms.
|
|
|
Things you can do to get your health
insurance to cover a clinical trial
cancer.gov
... still
an issue until 2014, when the Health Care Reform measure kicks in.
|
|
|
FDA describes evidence of Flu Vaccine efficacy
in health care facilities
WinPlayer Video
|
|
|
Abstracts reporting on t-cell lymphomas at
ASH 2010
|
|
|
How Not to Fight Colds
http://nyti.ms/gBPNHq
“Most of us come down with at least a couple of colds a year; children
get up to a dozen. But we all know people who seem never to catch one.
What’s their secret? Do they have extraordinarily robust immune systems,
and the rest of us, pathetically weak ones?”
|
|
|
|
|
|
Influenza Vaccine — Safe, Effective, and Mistrusted
http://bit.ly/hHyHQj
|
|
|
A Study Of anti-cd22 immunoconjugate (IO) Plus Rituximab For
Relapsed/Refractory Aggressive NHL Patients Who Are NOT Candidates For
Intensive High-Dose Chemotherapy
http://bit.ly/hBqoFd
IO is a humanized anti-CD22 antibody conjugated to calicheamicin, a
cytotoxic agent (antibody with chemo attached). IO targets CD22, which
is expressed in the majority of B-cell NHL.
2010 ASH report on IO:
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) +
Rituximab In Relapsed DLBCL Patients Followed by Stem Cell
Transplantation: Preliminary Safety and Efficacy
http://ash.confex.com/ash/2010/webprogram/Paper33326.html
|
|
|
|
|
|
IOM: Dietary Reference Intakes for Calcium and Vitamin D
http://bit.ly/fV2Ghh
Over the last ten years,
the public has heard conflicting messages about other benefits of these
nutrients—especially vitamin D—and also about how much calcium and
vitamin D they need to be healthy.
To help clarify this issue, the U. S. and Canadian governments asked the
Institute of Medicine (IOM) to assess the current data on health
outcomes associated with calcium and vitamin D. The IOM tasked a
committee of experts with reviewing the evidence, as well as updating
the nutrient reference values, known as Dietary Reference Intakes (DRIs).
|
|
|
study of interest: Vaccine Therapy With or Without
Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory
B-Cell NHL
http://bit.ly/farwZY
RATIONALE:
Vaccines, such
as dendritic cell therapy (DC) made from a person's tumor cells and
white blood cells may help the body build an effective immune response
to kill tumor cells. Cryosurgery kills cancer cells by freezing them.
Giving vaccine therapy together with cryosurgery may kill more tumor
cells. PURPOSE: This clinical trial studies giving vaccine therapy
together with or without cryosurgery in treating patients with residual,
relapsed, or refractory B-cell Non-Hodgkin's lymphoma
Also see preclinical rationale:
Combined Dendritic Cell Cryotherapy of Tumor Induces
Systemic Antimetastatic Immunity |
|
|
How far would you go to sustain the life of someone you
love, or your own?
http://to.pbs.org/eNFp1a
An excellent Frontline piece about end of
life issues, and the tradeoffs of modern medicine.
|
|
|
|
|
|
What Not to Say to a Depressed Person
By Therese J. Borchard
http://bit.ly/alzxrY
|
|
|
When do you move from living to
dying?
Nov 03 2010 Published by
Pal MD under Medical Musings, Medicine
http://bit.ly/bPhDS4
Toby writes: Good post!! Recommend to
all patients and caregivers!
|
|
|
Vaccination for Whooping Cough (Pertussis)?
PAL
|
|
|
Follicular Lymphoma: Emerging
Therapeutic Strategies:
Therapy for
Untreated FL
http://bit.ly/a18BZW
Nice overview by
Vaishalee P Kenkre1 and Brad S Kahl†1
|
|
|
Trial Search for relapsed DLBCL -
excluding stem cell transplant
http://bit.ly/aVbuVF
|
|
|
Standard Regimen is Still Most
Effective in Hodgkin's Lymphoma
http://bit.ly/9LFOnv
For patients with early
intermediate-stage Hodgkin's lymphoma,
standard therapy should remain the same.
That was the conclusion of a new study
that assessed the feasibility of using a
reduced dose of radiation or a more
intensive dose of chemotherapy.
The results of the study
demonstrated that lower doses of
radiation were not as effective as the
standard dose, when combined with
chemotherapy. Another finding was that a
more intensive chemotherapy (bleomycin,
etoposide, doxorubicin,
cyclophosphamide, Oncovin [vincristine],
procarbazine, prednisone; BEACOPP) was
not more effective than the current
standard regimen (Adriamycin
[doxorubicin], bleomycin, vinblastine,
and dacarbazine; ABVD) in this
population.
Before this study, it was
not clear what the optimal chemotherapy
regimen was, or what the most effective
dose of radiation was, explained lead
author Hans Theodor Eich, MD, PhD,
radiation oncologist at the University
of Cologne, Germany.
|
|
|
Letting Go: What should medicine do when it can’t save your life?
by Atul Gawande
http://nyr.kr/di8Mqi
JoJo writes: Amazing
article thanks. Aug 26th my 85 year old mother had a major stroke 10
days after getting a pace-maker. Dayle called me at work and I spoke to
the paramedics as they were transporting her. At the hospital my sister
and I were questioned about DNR's etc as we contacted my brother who
lives 3000 miles away. You think you are ready to deal with these
tragedies in our lives but we realized as a family we had not discussed
Mum's wishes. |
|
|
Theory, Observations, and Endpoints
http://bit.ly/973RMz
There was once a
time in history when doctors prescribed blood-letting, and were
convinced that it was effective – and could cite many success stories.
In comparison, homeopathy (water with trace amounts of different
compounds) along with good hygiene appeared effective! Each practice
(disproven by modern scientific methods) was based on a prevailing
theory and substantial clinical observation.
|
|
|
Carfilzomib - investigational agent that
similar to Velcade inhibits proteasome
system by by a different mechanism - see background and links to
trials
PAL
|
|
|
Novel Treatment Regimens for Waldenström’s Macroglobulinemia: Other
Drugs under Investigation in Waldenström's Macroglobulinemia
http://bit.ly/cxzcal
|
|
|
Clinical Questions that Can Only be Answered by Clinical Trials
http://bit.ly/cTBymX
|
|
|
|
|
|
Determinants of the optimal first-line therapy for follicular
lymphoma: A decision analysis
http://bit.ly/9xMJBK
"A significant limitation
of our study lies in the quality of data available for input into the
meta-analysis. Many of the trials examining these chemotherapy regimens
in patients with FL have only been published in abstract form. However,
practicing clinicians are forced to use these limited data when making
daily decisions about patient care.
In summary, using decision analysis methodology, we have shown that the
most important factor in maximizing quality-adjusted life years in
patients with advanced-stage, low-grade FL is the PFS (duration of
progression free survival) associated with the chosen therapy rather
than its short-term effect on QOL (quality of life). "
|
|
|
Tumor Lysis Syndrome in Patients with CLL
http://bit.ly/aHpGYF
|
|
|
Gemcitabine, vinorelbine, and pegylated liposomal
doxorubicin, GVD, a salvage regimen in relapsed Hodgkin's lymphoma:
CALGB 59804
annonc.oxfordjournals.org
GVD is a well-tolerated,
active regimen for relapsed HL with results similar to those reported
for more toxic regimens. High RRs in patients in whom prior transplant
failed confirms this regimen's activity even in heavily pretreated
patients |
|
|
|
|
|
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia:
Prevalence, Clinical Associations, and Prognostic Significance
http://bit.ly/boX70s
|
|
|
Cure Magazine: The Treatment Option You May Be Missing
http://bit.ly/bItRI7
|
|
|
Translational medicine provides new insight for
treating cutaneous lymphomas
http://bit.ly/9UQhU9
“Clinical observations
from the use of immune modulators and histone deacetylase (HDAC)
inhibitors are providing researchers with clues into the mechanism of
cutaneous T-cell lymphoma (CTCL), an expert says.”
|
|
|
|
|
|
Studies recruiting for DLBCL, not
eligible for transplant
http://bit.ly/aVbuVF
|
|
|
Overview: Stem Cell Transplant in Follicular Lymphoma
PAL
|
|
|
Personality Does Not Influence Cancer; Hypothesis
Should Be Retired
http://bit.ly/9m78qV
|
|
|
Conflict of Interest in Medical Decision-making
PAL
|
|
|
Zevalin as a Single Agent in Patients With Pretreated
B-Cell Lymphoma: Evaluation of the Long-Term Outcome
http://bit.ly/doQm0a
Overall response rate was
93% (53 of 57); complete response (CR) rate was 70% (40 of 57).
Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR)
with a median follow-up of 20 months (range, 10-42 months); 4 of them
still maintain their CCR after 36 months.
|
|
|
Evolving Questions in Follicular Lymphoma Highlighted
at International Hematology Meeting
http://bit.ly/90NUp5
|
|
|
Treatment-decisions - schema
PDF
|
|
|
Deep Venous Thromboses in Patients With Hematological
Malignancies After Peripherally Inserted Central (PICCs) Venous
Catheters
http://bit.ly/97jQtl
For patients with
hematologic cancer, changing from peripherally inserted central
catheters (PICCs) to centrally inserted tunneled, internal jugular
catheters dramatically reduced the incidence of catheter-associated deep
venous thrombosis. |
|
|
Reassessing the Standard of Care in Indolent Lymphoma:
A Clinical Update to Improve Clinical Practice CME/CE
medscape.com
|
|
|
Health Insurers Break Profit Records
as 2.7 Million Americans Lose Coverage
http://bit.ly/92JBoC
|
|
|
study of interest: Lenalidomide In Previously
Untreated, Advanced Stage Indolent Lymphoma
http://bit.ly/b3xIvp
|
|
|
Role of Radiation Therapy in Localized Aggressive
Lymphoma
jco.ascopubs.org
|
|
|
Webcam presentation by
registered dietician, Susan Dixon, Cancer Nuitrition specialist
|
|
|
|
|
|
Radioimmunotherapy for Other Lymphoma Subtypes and Indications
PAL
|
|
|
High Rates of Durable Responses in Relapsed NHL With Anti-CD22
Fractionated Radioimmunotherapy
http://bit.ly/9IbqxW
|
|
|
Study Finds Consumers Need Education
Regarding Evidence-based Care
http://bit.ly/99N18b
|
|
|
NEJM: Buying Health Care, the Individual Mandate, and the
Constitution
http://bit.ly/9FElMG
|
|
|
Comments on the PRIMA
study and how to measure success of first line maintenance Rituxan
PDF
|
|
|
GS-9219 A Novel agent with Potent Antineoplastic Activity in Dogs with
Spontaneous NHL
http://clincancerres.aacrjournals.org
About nucleotide analogue GS 9219 (NCI)
Formulated to
selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is
converted to its active metabolite, PMEG diphosphate (PMEGpp), via
enzymatic hydrolysis, deamination, and phosphorylation; subsequently,
PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which
may result in the termination of DNA synthesis, S-phase cell cycle
arrest, and the induction of apoptosis in susceptible lymphoma cell
populations.
A Trial of GS-9219 in CLL, NHL or MM
http://clinicaltrials.gov
(has
completed enrollment) |
|
|
The effects of β-glucan on human immune and cancer cells
Chan, et al. J Hematol Oncol. 2009; 2: 25. http://bit.ly/cIBT0P
|
|
|
Targeted Therapies for Lymphoma
Tutorial, NCI
http://bit.ly/cF17bg
A bit advanced, but with excellent illustrations and good background on
lymphomas. |
|
|
Walking the Tightrope of Health Insurance Reform between 2010 and
2014
http://bit.ly/azJJgH
|
|
|
Clinical Questions that can only be answered by trials
PDF
|
|
|
Beautifully written.
I
expect this piece will resonate with patients and experts alike.
Musings of a Distractible Mind:
Thoughts of a moderately strange (yet not harmful) primary care
physician.
A Letter to Patients With Chronic Disease
http://bit.ly/b68MKj
|
|
|
Response to Second-line Therapy Defines the
Potential for Cure in Patients with Recurrent DLBCL: Implications for the Development of Novel
Therapeutic Strategies
http://www.medscape.com/viewarticle/723577
"No clear indication exists that palliative approaches are
inferior to further intensive approaches in this setting. This
fact may make a comfort-directed or investigational strategy
more acceptable to some patients, because they do not risk
losing the chance for a cure by choosing an alternative to
established standard chemotherapy regimens."
|
|
|
A 19 page comic strip explanation of homeopathy
http://bit.ly/bYNidX
|
|
|
Targeting PD-1
to modulate immune
response against lymphoma
Clinical Report:
http://bit.ly/a3lHUc
Clinical Trials:
http://bit.ly/1Bj7r1
|
|
|
CHOP-R + bortezomib (Velcade)
as initial therapy for DLBCL
http://bit.ly/9ifYVY
|
|
|
Survey Results:
Patient Preference of
Chemo-based Therapy
following
Relapse
of indolent follicular lymphoma (Completed)
PAL
|
|
|
Advocacy Alert: Contact your
Elected representatives - ask them to support House Resolution 143 to make
September Blood Cancer Awareness Month.
PAL
|
|
|
Panobinostat Produces Objective Responses in Advanced Hodgkin's Lymphoma
http://bit.ly/bHEBIb
"Of 129 patients, 4
(3%) had a complete response to panobinostat, 29 (22%) had a partial
response (defined as a reduction of tumor size by a least 50%), and 111
were deemed to have disease control (defined as a combination of
complete and partial responses and stable disease)
A ceiling is likely going to be reached in relapsed/refractory patients,
and the major questions are going to be: Is there sufficient independent
activity for efficacy, such as in maintenance?" he said. "Is there
synergy, and is it feasible to combine this agent with other therapies?
And are there predictive biomarkers?"
|
|
|
Study of interest: Combination Veltuzumab (Anti-CD20) and Fractionated
90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With
Follicular Lymphoma
http://bit.ly/c80PPu
|
|
|
|
|
|
Transparency at the Food and Drug Administration
http://bit.ly/cGqhip
"More than 30 years ago,
FDA Commissioner Donald Kennedy noted "a basic principle of
our political system [is] that people affected by
governmental decisions have a right to know the basis on
which they are made." With the daily practice of medicine
routinely affected by the decisions of the FDA, the medical
community has a large stake in transparency at the agency. The
full set of draft proposals can be found on the FDA's Web site
(www.fda.gov/transparency)."
|
|
|
What is responsible for the recent improvements in outlook for
patients with follicular lymphoma?
http://bit.ly/dev1l0
|
|
|
Hitting the sweet spot for lymphoma
http://bit.ly/d7bnsS
Targeted
delivery of liposomal doxorubicin to CD22.
“As envisioned by scientists as far back as the 1800s, the
ideal chemical therapy would possess exquisite selectivity,
thereby restricting, if not eliminating, collateral cellular
damage (eg, Ehrlich's "magic bullet").”
|
|
|
"Natural Cancer Treatments," a Review by Steven Novella,
MD.
http://bit.ly/c6T5IU
|
|
|
ASCO 2010 Wrap-up: Converting Cancer to a Chronic Disease
medscape.com
|
|
Marginal zone lymphomas - Factors that affect outcome
interscience.wiley
|
|
|
Questions to ask about drug risks, Harlan M. Krumholz MD, SM,
http://bit.ly/bP4BLA
"Doctors cannot tell you
what will happen. The best they can do is to be clear about what is
known about the options -- and what remains uncertain."
|
|
|
The Path to Personalized Medicine
http://bit.ly/amxlBF
Margaret A. Hamburg, M.D., and Francis S. Collins, M.D., Ph.D.
As the leaders of the
National Institutes of Health (NIH) and the Food and Drug
Administration (FDA), we have a shared vision of personalized
medicine and the scientific and regulatory structure needed
to support its growth. Together, we have been focusing on the
best ways to develop new therapies and optimize prescribing by steering patients to the right drug at the right dose at
the right time.
|
|
|
The Interface Between Cancer and Psychiatry
http://bit.ly/d8JSoj
"As
a psychiatrist who has lymphoma, I have developed a deep understanding
of the ways in which our training can help us help patients who find
themselves forced to deal with the complicated emotional aspects that
accompany various forms of cancer. ...
Cancer is an alienating and existential experience. I know of no other
common disease that immediately causes so much fear, anxiety,
depression, confusion, and sense of impending disaster in a patient or
his or her significant others as when they hear the word cancer for the
first time."
|
|
|
ACS cites studies on Access to Healthcare for Cancer Survivors
http://bit.ly/bYMcXT
|
|
|
Dr. Cheson: ASCO lymphoma highlights 2010
http://bit.ly/aHIN0Q
Important talk. Do give a
listen. |
|
|
Many studies great news for mice, not so much for humans
us.cnn.com
"In terms of cancer, it is
difficult to translate animal models to human applications because a
human tumor takes several years to develop, and rodent studies often
just inject human tumors into the rat or mouse, said Dr. Gabriel Lopez-Berestein,
professor of medicine and cancer biology at the University of Texas M.D.
Anderson Cancer Center." |
|
|
How to Think about Future Health Care
Spending,
NEJM, Fuchs, Ph.D.
http://bit.ly/cCkLwe
"Lost in the din are two
critical
problems related to future spending — one
empirical, the other conceptual."
|
|
|
PRIMA data for maintenance Rituxan:
Draft Discussion and Questions
PDF |
Send
Comments |
|
|
Guidelines Call for Cancer Patients to Get Moving
http://bit.ly/bSoetK
"The primary
objective of prescribing exercise to cancer patients and survivors is to
help them regain and improve physical function, said Dr. Schmitz of the
center for clinical epidemiology and biostatistics at the University of
Pennsylvania in Philadelphia. Exercise can also help improve body image
and quality of life for these patients."
|
|
|
Emotional Patients Do Not Perceive Medical Consultations and Advices
http://bit.ly/axdznz
|
|
|
Oral green tea in asymptomatic, Rai stage 0-II CLL
AbstView_74_47574
Comment: Here are reported
what appears to be good signals of activity and relatively modest side
effects at the chosen dose (compared to other CLL treatments).
Note that there were also toxicities at what appears to be the active
dose - including signals of liver toxicities - transaminitis (31% grade
1, 12% grade 2), and nausea in 55%. These are modest side effects
compared to standard CLL treatments, but this has to be weighed against
no treatment, because treatment is not given for early stage CLL.
When estimating the treatment effects you need to consider also the
natural history of the condition in the selected population, in this
case early stage CLL ... What is its typical clinical course? Does it
wax and wane? How long until treatment is needed? I think it can be ten
years or more. So are these clinically meaningful responses -
leading to better quality of life or survival? If anything,
quality of life was impaired by the side effects (up to 6 months of
nausea in 55%), so long term impacts on survival - or time to first
treatment (compared to observation in a controlled study) could be the
key questions going forward. |
|
|
Treatment of HIV-associated Hodgkin's lymphoma (HIV-HL): Results of
a prospective multicenter trial
http://bit.ly/9h1Tc3
"Conclusions:
In pts with HIV-HL risk-adapted CT and concomitant HAART is feasible and
effective. However, pts must closely be monitored for neutropenic
infections. These data suggest that the prognosis of HIV-HD may approach
results achieved in the HIV-negative population with HL." (Which
is very good indeed.) |
|
|
Hypogammaglobulinemia (hypogam) in patients receiving Rituxan and
the impact of Rituxan maintenance
http://bit.ly/cYmqll
We identified 215 pts
treated with R for lymphoma between 12/1998 and 4/2009 and also had
quantitative serum immunoglobulin levels (sIg) evaluated prior to and
after treatment with R. Data on the use of IVIG was collected. ...
Rituxan was associated
with developing hypogam in 39% of pts with normal baseline sIg. Pts
receiving RM (Rituxan maintenance) had a significantly higher risk of
developing hypogam and requiring IVIG. The risk of symptomatic hypogam
should be considered in the use of R maintenance.
|
|
|
Meta-analysis of risk for lymphoma with immunomodulators for
inflammatory bowel disease
http://bit.ly/aFd4kp
|
|
|
Extranodal lymphomas
http://bit.ly/a6AhWt
Emanuele Zucca and Franco
Cavalli |
|
|
Complete response rates with Lenalidomide (Revlimid) plus rituximab
for untreated indolent B-cell NHL
http://bit.ly/dBQerx
"28 pts were
evaluable for response. The overall response rate was 86%.
Complete responses (CR)
were attained in 79% (65% CR/14% CRu) of pts, 2 pts (7%) had a partial
response, and stable disease was seen in 4 (14%). Response rates were
impressive in follicular lymphoma, with nearly all patients 16/17 (94%)
attaining a CR. At a median follow up of 14.1 (9.7-18.8) months, one
patient experienced progression of disease."
|
|
|
Lenalidomide (LEN) in patients with transformed lymphoma: Results
from a large international phase II study (NHL-003).
http://bit.ly/a234dx
"LEN has promising
clinical activity and achieves durable responses in patients with TL.
Also, it may be necessary to consider the original histology when
setting a course of therapy for patients with TL. Further studies are
needed in this hard-to-treat population."
|
|
|
Low Absolute Lymphocyte Count (ALC) associated with relapse in DLBCL
http://bit.ly/cPITVc
"Patients with an ALC
>/=0.96 x 10(9)/l (N=103) had a cumulative incidence of relapse of 6
versus 79% with an ALC <0.96 x 10(9)/l (N=46) (P<0.0001). This study
suggests that lymphopenia measured by ALC can be used as a marker to
assess risk of DLBCL relapse during routine follow-up after standard
chemotherapy.
Comment: As always, it will be important for another group to replicate
the finding. |
|
|
Yoga Eases Sleep Problems Among Cancer Survivors
http://healthday.com/Article.asp?AID=639340
Study found those who
practiced it for four weeks after chemo slept better, used fewer sleep
aids |
|
|
Radioimmunotherapy of Lymphoma: Ahead of Its Time or Past Its
Sell-By Date?
http://bit.ly/9x2RgL
Tim Martin Illidge, School
of Cancer and Imaging Sciences, Manchester Academic Health Sciences,
University of Manchester, Manchester, United Kingdom
As we look to the future, few things are certain, but we can be sure
that there will continue to be increasing numbers of patients with
follicular lymphoma who are refractory to both chemotherapy and
rituximab. For the latter group, there are compelling data that RIT can
play an important role in both chemotherapy- and rituximab refractory
disease, leading to high response rates with durable remissions.
|
|
|
Improved survival in patients with early stage low-grade follicular
lymphoma treated with radiation therapy (RT)
http://bit.ly/cHNXNh
N = 6,568.
Overall Survival at 5, 10, 15, and 20 years in the RT
group was 81%, 62%, 45%, and 35% versus 71%, 48%, 34%, and 23% in
patients not receiving RT. RT for early stage low-grade follicular
lymphoma is greatly underused in the US population; increased use of
upfront RT could prevent thousands of deaths from lymphoma in these
patients. |
|
|
Poverty of Riches - analysis of number of lymphoma studies versus
available patients
PDF
|
|
|
Radioimmunotherapy Consolidation in Mantle Cell Lymphoma
http://bit.ly/9kt6WK
PDF
http://bit.ly/c7HIxm
Wojciech Jurczak, European
Oncological Disease - Published: October 2008
A thorough description of the rationale for consolidation with RIT for
MCL – but also informative for other lymphomas.
|
|
|
Orac: The never-ending saga of DCA -
dichloroacetate as a cancer treatment
http://bit.ly/cbfTVJ
"I don’t say this because
I want DCA to fail; I say it because I would very much like to see DCA
succeed." |
|
|
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular
NHL: Long-Term Outcome of the EORTC 20981 Phase III Randomized
Intergroup Study
http://bit.ly/9mVxh5
|
|
|
|
|
|
CVP followed by Bexxar in Untreated
Follicular Lymphoma:
Eight-Year Follow-Up of a Multicenter Phase II Study
http://bit.ly/chKTgk
After a median follow-up of 8.4 years, the median
response duration had not been reached (range, 3 to 111+ months).
COMMENT: Encouraging, but once again, we have a Bexxar study design that
suffers from being small (n=30) and having no randomized comparator –
such as CVP-R. Further it supports the FIT study which demonstrated
that chemo followed by RIT consolidation is very much worth considering
– that study used Zevalin.
Regarding the risk factors in this study population, which is a problem
when comparing results across studies (historical controls) – that 15 of
the participants had bulky disease suggests that at least 50% had high
risk FL. ~ KarlS (layperson perspective)
|
|
|
Lifestyle Factors Significantly Impact
Survival Of Lymphoma Patients
http://bit.ly/cZZB7S
"Most importantly, we
didn't answer the question of whether changing these factors after
diagnosis would impact survival," he says. "That is best done with a
clinical trial." |
|
|
Gene Expression Signature of Host Immune
Response Is Predictive of Follicular Lymphoma Patient Survival in
Independent Cohorts, and Correlates with Transformation to Diffuse Large
B-Cell Lymphoma
ASH 2009
|
|
|
Statin Use by Donors May Protect Stem Cell
Transplant Patients From Graft Versus Host Disease
http://bit.ly/8ZNK88
In a retrospective
study of 567 patients who underwent hematopoietic cell transplantation
from matched sibling donors between 2001 and 2007, patients whose donors had been taking statins at the
time of stem cell donation experienced no severe acute GVHD.
|
|
|
REDUCING ENVIRONMENTAL CANCER RISK
What We Can Do Now
http://bit.ly/bAe3hu
|
|
|
Too many vitamin tablets could be bad for your health
http://bit.ly/aeM43O
|
|
|
Wilm's Tumor 1 Protein Vaccine ... for relapsed NHL after allo SCT
Patients with the blood antigen HLA-A2 and the WT1 cancer protein who
have persistent or recurrent blood cancers after [allo] stem cell
transplantation.
Background: "Most patients [with blood cancers] including NHL have a
protein called Wilm's Tumor 1 (WT1) in their cancer cells. This protein
is thought to be able to influence the growth of these cancers.
A vaccine made with the WT1 protein may boost the immune system to help
fight these cancers in patients whose cancer cells contain the protein."
http://bit.ly/cGFFDG
|
|
|
Low Dose Naltrexone – Bogus or Cutting Edge Science?
http://bit.ly/aIACkO
A scholarly examination of how “science is abused in the pursuit of
health (or making money from those who are pursuing health).”
|
|
|
Primary Radiation Therapy in Patients With Localized Orbital
MALT Lymphoma
http://bit.ly/9YUyKD
Forty-three patients (93%)
achieved complete remission (CR), and three patients (7%)
achieved partial remission (PR). Five-year relapse-free
survival, cause-specific survival, and overall survival were
93%, 100%, and 100%, respectively.
|
|
|
Novel antibodies in the treatment of lymphoma,
S.A. Bhat,
M.S. Czuczman
http://bit.ly/ccYZkg
|
|
|
Rituximab maintenance therapy: a step forward
in follicular lymphoma
http://bit.ly/9pncbR
|
|
|
Talking to Your Doctor about Cancer-Related Symptoms
http://bit.ly/dgctDj
"Because symptoms are what
you experience, your healthcare providers can only know about
your symptoms if you tell them. This puts you in the unique position of
being the symptoms expert. Other people may not realize when or how much
you hurt, that you’re exhausted and sleeping poorly, that you’ve lost
your appetite, or that you’re feeling distressed." by Charles S.
Cleeland, PhD, with Diana Lazzell |
WellPoint Insurance Company routinely targets breast cancer patients
http://bit.ly/bfhTad
"That tens of thousands of
Americans lost their health insurance shortly after being diagnosed with
life-threatening, expensive medical conditions has been well documented
by law enforcement agencies, state regulators and a congressional
committee. Insurance companies have used the practice, known as
"rescission," for years. And a congressional committee last year said
WellPoint was one of the worst offenders."
Battling the Hematological Malignancies: The 200 Years' War
http://bit.ly/bnfGDv
"As we move to consider these tumors by
their genetic abnormality (genotype) rather than their cellular
appearance (phenotype), one converts the generalities of leukemia,
lymphoma, and myeloma into hundreds of diseases with distinct genetic
causes, clinical manifestations, and drug responsiveness."
Voluntary Ethics Code Set for Medical Organizations
healthday.com
Role of SCT in treatment of Follicular Lymphoma - and
evidence-based review
http://bit.ly/d4QBN4
Decreasing Incidence of Gastric MALT Lymphomas in the Era of
Anti-Helicobacter pylori Interventions
http://bit.ly/c0hEQk
|
|
|
Allergic to Rituxan? Rapid Drug Desensitization can enable you to
take it.
http://bit.ly/aROY6G
"413 desensitizations were performed, 94% of which
induced limited or no side effects. During desensitizations, no
life-threatening HSRs or deaths occurred, and all patients received
their full target dose.
|
